ReviewCalcified tissue international2026
Piezo1, Integrins, and YAP/TAZ in Osteoporotic Mechanotransduction: Key Pathways, Crosstalk, and Therapeutic Implications.
Review in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a systemic skeletal disorder fundamentally characterized by an imbalance between bone formation and bone resorption, ultimately leading to reduced bone mass, microarchitectural deterioration, and increased fracture susceptibility. As bone is a highly mechanoresponsive tissue, mechanical stimulation is indispensable for the maintenance of skeletal homeostasis, and insufficient loading is a recognized driver of bone loss. In recent years, Piezo1, integrins, and YAP/TAZ have emerged as key nodes in bone cell mechanotransduction. Piezo1 functions primarily as a mechanosensitive ion channel that converts membrane deformation into calcium-dependent intracellular signaling, integrins mediate extracellular matrix adhesion and focal adhesion-based force transduction, and YAP/TAZ act as nuclear effectors that translate mechanical inputs into transcriptional programs. Increasing evidence indicates that these pathways do not function independently but are organized into a complex and dynamic signaling network that governs osteocyte mechanosensation, osteoblast differentiation, mesenchymal stem cell fate determination, and osteoclast-related remodeling responses. Dysregulation of this mechanotransduction axis has been implicated in aging-related bone loss, estrogen deficiency-induced osteoporosis, and unloading-associated skeletal deterioration. Moreover, these pathways are increasingly being recognized as potential therapeutic targets for osteoporosis, with translational strategies ranging from pharmacological modulation to biomaterial-guided and mechanically assisted interventions. This review summarizes the roles of Piezo1, integrins, and YAP/TAZ in osteoporotic mechanotransduction, emphasizes their crosstalk in the membrane-to-nucleus signaling continuum, and discusses future research priorities, particularly cell specificity, spatiotemporal heterogeneity, and translational applications in precision skeletal medicine. In the revised version, we further distinguish experimentally validated links from proposed models, define the hierarchy of Piezo1-, integrin-, and YAP/TAZ-dependent signaling across osteocytes, osteoblast-lineage cells, BMSCs, and osteoclast/macrophage-lineage cells, and emphasize context-dependent controversies that are essential for therapeutic translation.
Indexed as
Identifiers
42503528What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.